1. Erthygl › Ymchwil › Adolygwyd gan gymheiriaid
2. Cyhoeddwyd

   Understanding medication compliance and persistence from an economics perspective

   Hughes, D., Elliot, R. A., Shinogle, J. A., Peele, P., Bhosle, M. & Hughes, D. A., 1 Ion 2008, Yn: Value in Health. 11, 4, t. 600-610

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

3. Cyhoeddwyd

   Use Of The Ims Core Diabetes Model (CDM) In A Long-Term Projected Health Economic Comparison Of CSII And MDI Treatments Of Type 1 Diabetes (T1D) In A Newly-Diagnosed Population Of Paediatric Patients

   Ridyard, C., Blair, J. & Hughes, D., 20 Hyd 2017, Yn: Value in Health. 20, 9, t. A580

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

4. Cyhoeddwyd

   Using Routinely Recorded Data in a UK RCT: A Comparison to Standard Prospective Data Collection Methods

   Powell, G., Bonnett, L., Tudor-Smith, C., Hughes, D., Williamson, P. R. & Marson, A. G., 5 Gorff 2021, Yn: Trials. 22, 1, 429.

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

5. Cyhoeddwyd

   Using Routinely Recorded Data in the UK to Assess Outcomes in a Randomised Controlled Trial: The Trials of Access

   Powell, G., Bonnett, L., Smith, C. T., Hughes, D., Williamson, P. & Marson, A., 23 Awst 2017, Yn: Trials. 18, 11 t., 389.

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

6. Cyhoeddwyd

   Utilising Benefit-Risk Assessments within Clinical Trials – A Protocol for the BRAINS project

   Totton, N., Julious, S., Hughes, D., Cook, J., Biggs, K., Coates, L., Cook, A., Hewitt, C. & Day, S., 19 Ion 2021, Yn: Trials. 22, 68.

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

7. Cyhoeddwyd

   Valuations of epilepsy-specific health states: a comparison of patients with epilepsy and the general population

   Hughes, D., Mulhern, B., Rowen, D., Snape, D., Jacoby, A., Marson, T., Hughes, D. A., Baker, G. & Brazier, J., 1 Gorff 2014, Yn: Epilepsy and Behavior. 36, t. 12-17

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

8. Cyhoeddwyd

   Value assessment and quantitative benefit-risk modelling of biosimilar infliximab for Crohn’s disease

   Catt, H., Bodger, K., Hughes, D. & Kirkham, J. J., Rhag 2019, Yn: PharmacoEconomics. 37, 12, t. 1509-1523 15 t.

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

9. Cyhoeddwyd

   Value of improving patient safety: Health-economic considerations for Rapid Response Systems – a Rapid Review of the Literature and Expert Round Table

   Subbe, C., Hughes, D., Lewis, S., Holmes, E., Kalkman, C. J., So, R. K., Tranka, S. & Welch, J., 17 Ebr 2023, Yn: BMJ Open. 13, 4, e065819.

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

10. Cyhoeddwyd

    Value-Based Pricing: Incentive for Innovation or Zero Net Benefit?

    Hughes, D. & Hughes, D. A., 1 Medi 2011, Yn: Pharmacoeconomics. 29, 9, t. 731-735

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

11. Cyhoeddwyd

    Warfarin pharmacogenetics: Economic considerations.

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Ion 2007, Yn: Pharmacoeconomics. 25, 11, t. 899-902

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid